Table 3: Summary of Oncolytic Vectors and Clinical Trials

HSV Strain	Genetic Modification	Therapeutic Transgenes	Stage	Clinical Indications	Ref.
dlsptk	tk deletion	none	Preclinical		[148, 240]
hrR3	UL39 disruption (large RR subunit)	none	Preclinical		[155, 241, 242]
HSV1716	Deletion in both copies of ICP34.5	none	Human clinical trials Phase I (recruitment not yet open)	Glioma, melanoma, head-and-neck cancer. Non-CNS solid tumours	[167, 169, 170, 243, 244]
R3616	Deletion in both copies of ICP34.5	none	Preclinical		[151, 157]
R4009	Stop codon in both copies of ICP34.5	none	Preclinical		[151, 157]
G207	Deletion in both copies of ICP34.5 + disruption of UL39	none	Human clinical trials phase I, IB, and II	Recurrent brain cancer (glioma, astrocytoma, glioblastoma	[161-165, 245, 246]
MGH-1	Deletion in both copies of ICP34.5 + disruption of UL39	none	Preclinical		[149, 166]
MGH-2	Deletion in both copies of ICP34.5 + disruption of UL39	CYP2B1 and shiCE	Preclinical		[190]
R7020 (NV1020)	Deletion in one copy of ICP34.5 + tk under ICP4 promoter control + deletion in UL24, 55 and 56	none	Human clinical trials phase I and II	Liver, metastases derived from colorectal cancer.	[121, 122, 176, 177]
G47Δ	Deletion in both copies of ICP34.5 + disruption of UL39	none	Preclinical		[144]
Myb34.5	Deletion in both copies of ICP34.5 + disruption of UL39 + insertion of an ICP34.5 gene under the control of the B-myc promoter	none	Preclinical		[247, 248]
DF3γ34.5	Deletion in both copies of ICP34.5 + insertion of an ICP34.5 gene under the control of the DF3/MUC1 promoter	none	Preclinical		[139, 249]
HF10	Spontaneous generation of HSC-1 variant	none	Human clinical trials		[215, 216]
NV1042	HSV-1/HSV-2 intertypic recombinant + contains only one ICP34.5 copy	Murine IL-12	Preclinical		[192-195]
OncoVexGM-CSF	Deletion in both copies of ICP34.5 + deletion of ICP47	GM-CSF	Phase II/III	Breast cancer, head-and-neck cancer, melanoma	[160, 250]
RAMBO	Deletion in both copies of ICP34.5 + UL39 disruption	IE4/5 prom-Vstat120	Preclinical		[214]
NP2 enkephalin expressing vector	Deletions in ICP4, 27, 22 and 47	human preproenkephalin	Phase I	Chronic pain from terminal cancer	[38, 39]